Skip to main content
PPCB logo

Propanc Biopharma, Inc.

PPCBNASDAQHealthcareBiotechnology

$0.34Today:- (-)1Y −78.39%

As of Oct 15, 2026 close

Market cap
$383.75K
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.16$6.79
Volume (live)
-
Avg. volume (3M)
290.37K

Propanc Biopharma (PPCB) Income Statement

In fiscal 2026 (fiscal year ended Jun 30, 2026), Propanc Biopharma posted a net loss of $18.86M, compared with a net loss of $58.92M a year earlier.

Propanc Biopharma Income Statement Analysis

Values in millions USD

Scroll to see more
Propanc Biopharma, Inc. income statement - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Sep 2019Jun 2018Jun 2017
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.000.000.000.00
Cost of Revenue0.020.000.020.020.000.000.000.000.000.00
Gross Profit-0.020.00-0.02-0.02-0.010.000.000.000.000.00
Operating Expenses
Research & Development0.630.220.250.250.260.230.180.261.830.97
Selling, General & Administrative15.2857.051.291.531.731.583.312.352.134.77
Operating Expenses18.1957.281.541.781.991.813.492.613.965.74
Operating Income-18.19-57.28-1.54-1.78-1.99-1.81-3.49-2.62-3.96-5.74
Other Income/Expense
Interest Income0.000.000.000.000.010.00-0.000.00-
Interest Expense0.430.560.670.53-0.570.451.751.322.793.20
Other Income/Expense-0.68-1.080.25-0.48-0.72-0.33-1.38-3.26-3.26-2.43
Income
Income Before Tax-18.86-58.92-1.95-2.79-2.71-2.14-4.88-5.87-7.22-8.17
Income Tax Expense0.000.00-0.13-0.13-0.05-0.11-0.14-0.12-0.18-0.31
Net Income-18.86-58.92-1.82-2.66-3.36-2.03-4.74-5.76-7.04-7.87
Net Income - Continuous Operations-18.86-58.92-1.82-2.66-2.66-2.03-4.74-5.76-7.04-7.87
Net Income - Discontinued Operations----------
EBITDA-18.18-58.34-1.26-2.23-1.99-1.69-3.13-4.56-4.43-4.97
EBIT-18.19-58.36-1.28-2.26-1.99-1.81----
Depreciation & Amortization0.020.020.020.020.000.000.000.000.000.00
Earnings Per Share
Basic EPS-18.00-371.00-6312.00-781710.00-2953800.00-20000.00-4811229.00-274239389.00-4468737.00-28018162.00
Diluted EPS-18.00-371.00-6312.00-781710.00-2953800.00-20000.00-4811229.00-274239389.00-4468737.00-28018162.00
Basic Shares Outstanding1.120.160.000.000.000.00-0.000.000.00
Diluted Shares Outstanding1.120.160.000.000.000.00-0.000.000.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Propanc Biopharma Financial Statements

Is Propanc Biopharma profitable?

No. Propanc Biopharma reported a net loss of $18.86M in fiscal 2026. In fiscal 2025 it lost $58.92M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition